- The probability of death will double in the next 10 years if middle-aged and elderly people can’t stand on one foot for 10 seconds
- Maradona death: Medical team members will be tried for alleged murder
- Tuberculosis infection in Singapore: About 30% of the 574 people in the same community positive
- Swollen axillary lymph nodes associated with the COVID-19 vaccine last longer than initially reported
- How to relieve the fatigue symptoms of patients with Parkinson’s disease?
- Frontiers in Oncology: Mushroom extract can clear HPV infection
Pfizer COVID-19 oral drug Paxlovid: One Phase II/III clinical trial failed
- How long can the patient live after heart stent surgery?
- More than 500 new drugs for blood diseases are in development
- Keytruda: The 5-year survival rate for advanced lung cancer doubled!
- Amylyx released the latest statistical analysis of new ALS drugs after being opposed by FDA panel last month
- Celine Dion is paralyzed due to muscle cramps: What are Muscle Cramps?
- Taiwan death from COVID-19 vaccination exceeds death from COVID-19
- The world top 5 best-selling drugs in 2020
Pfizer COVID-19 oral drug Paxlovid: One Phase II/III clinical trial failed.
On June 15, Pfizer announced a Phase II/III clinical (EPIC-SR) study of the COVID-19 oral drug Paxlovid in unvaccinated adults and vaccinated adults with one or more risk factors for progression to severe disease result.
However, the primary endpoint of sustained relief of all symptoms for 4 consecutive days was not met, and the secondary endpoint was not statistically significant.
Specifically, results of an interim analysis previously reported in December 2021 showed that the primary endpoint of sustained 4-day remission of COVID-19 symptoms was not met, and the key secondary endpoint was a 70% reduction in the relative risk of hospitalization or death (treatment arm: 3/428; Placebo: 10/426), not statistically significant.
Results of the latest analysis of 1,153 patients enrolled as of December 2021 showed a 51% relative risk reduction in hospitalization or death (treatment group: 5/576; placebo: 10/569), which was not statistically significant; for 721 patients A subgroup analysis of vaccinated adults with at least one risk factor for progression to severe COVID-19 showed a 57% reduction in the relative risk of hospitalization or death (treatment group: 3/361; placebo: 7/360).
Medical Rubik’s Cube info
(source:internet, reference only)